Alemtuzumab: Additional Phase II data

Follow-up data from the open-label, U.S. and European Phase II CAMMS223 trial in 334 patients showed that alemtuzumab reduced the risk for relapse by 72% and the risk for sustained accumulation of disability (SAD) by 73% at 4 years compared with Rebif interferon beta-1a (p<0.001 for each). The annualized relapse rate for alemtuzumab was 0.10 and 0.33 for Rebif. The improvement in mean disability score observed at month 36 for patients treated with alemtuzumab was maintained through month 48. Data were presented at the European Committee for Treatment and Research in Multiple Sclerosis meeting in Dusseldorf. The companies had previously reported that alemtuzumab met both co-primary endpoints of time to sustained SAD and relapse rate at 3 years (see BioCentury, Oct. 22, 2007 & Oct. 27, 2008). ...